3 assets in Childhood Ependymoma

Therapeutic assets addressing Childhood Ependymoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Childhood Ependymoma	National Cancer Institute (NCI)	P2	CCC (53)
Pembrolizumab Childhood Ependymoma	National Cancer Institute (NCI)	P1	CC (43)
Sotigalimab Childhood Ependymoma	Pediatric Brain Tumor Consortium	P1	CC (42)